Citations

Showing 10 of 108119 citations.

Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy
Bobart, Shane A. , Han, Heedeok, Tehranian, Shahrzad , Vriese, An S. De , Roman, Juan Carlos Leon, Sethi, Sanjeev , Zand, Ladan , Gomez, Cristina Andrades, Giesen, Callen D., Soler, María José , Bomback, Andrew S., De Vriese, An S , Soler, Maria Jose , Bobart, Shane A , Han, Heedeok, Tehranian, Shahrzad , Roman, Juan Carlos Leon, Sethi, Sanjeev , Zand, Ladan , Gomez, Cristina Andrades, Giesen, Callen D., Bomback, Andrew S., Fervenza, Fernando C

Mayo Clinic

Clinical Journal of the American Society of Nephrology | November 15, 2021 | Volume: 16 | Issue: 12 | Pages: 1833-1839

10.2215/cjn.05480421 | PMID 34782349 Get It

Background and objectives Kidney biopsy is the current gold standard to diagnose membranous nephropathy. Approximately 70%–80% of patients with primary membranous nephropathy have circulating anti-phospholipase A2 receptor antibodies. We previously demonstrated that in proteinuric patients with preserved eGFR and absence of associated conditions ( e.g., autoimmunity, malignancy, infection, drugs, and paraproteinemia), a positive anti-phospholipase A2 receptor antibody test by ELISA and immunofluorescence assay confirms the diagnosis of membranous nephropathy noninvasively. These data have not been externally validated. Design, setting, participants, & measurements The clinical and pathologic characteristics of patients with a positive anti-phospholipase A2 receptor antibody test at the Mayo Clinic, the University Hospital Vall D’Hebron (Barcelona), and the Columbia University Medical Center (New York) were retrospectively reviewed. Biopsy findings and presence or absence of a potential associated condition were assessed. Results From a total of 276 patients with positive anti-phospholipase A2 receptor serology, previously reported patients ( n =33), kidney transplant recipients ( n =9), pediatric patients ( n =2), and patients without kidney biopsy ( n =69) were excluded. Among the 163 remaining patients, associated conditions were identified in 47 patients, and 15 patients had diabetes mellitus. All 101 patients of the final cohort had a primary diagnosis of membranous nephropathy on kidney biopsy. In the 79 patients with eGFR≥60 ml/min per 1.73 m 2 , none of the biopsy findings altered diagnosis or management. Among the 22 patients with decreased eGFR, additional findings included superimposed acute interstitial nephritis ( n =1). Conclusions In patients with preserved eGFR and absence of associated conditions or diabetes, a positive anti-phospholipase A2 receptor test by either ELISA >20 RU/ml or a positive immunofluorescence assay confirms the diagnosis of membranous nephropathy, precluding the requirement for a kidney biopsy.
Post-Acute Sequelae of COVID-19 and Cardiovascular Autonomic Dysfunction: What Do We Know?
Bisaccia, Giandomenico , Ricci, Fabrizio , Recce, Vittoria, Serio, Antonio, Iannetti, Giovanni , Chahal, C. Anwar A. , Fedorowski, Artur , Gallina, Sabina , Chahal, Choudhary Anwar A , Fedorowski, Artur , Ricci, Fabrizio , Serio, Antonio, Ståhlberg, Marcus , Khanji, Mohammed Y

Mayo Clinic

Journal of Cardiovascular Development and Disease | November 15, 2021 | Volume: 8 | Issue: 11 | Pages: 156

10.3390/jcdd8110156 | PMID 34821709 Get It

Post-acute sequelae of SARS-CoV-2 (PASC), or long COVID syndrome, is emerging as a major health issue in patients with previous SARS-CoV-2 infection. Symptoms commonly experienced by patients include fatigue, palpitations, chest pain, dyspnea, reduced exercise tolerance, and “brain fog”. Additionally, symptoms of orthostatic intolerance and syncope suggest the involvement of the autonomic nervous system. Signs of cardiovascular autonomic dysfunction appear to be common in PASC and are similar to those observed in postural orthostatic tachycardia syndrome and inappropriate sinus tachycardia. In this review, we report on the epidemiology of PASC, discuss current evidence and possible mechanisms underpinning the dysregulation of the autonomic nervous system, and suggest nonpharmacological and pharmacological interventions to treat and relieve symptoms of PASC-associated dysautonomia.
Machine Learning Consensus Clustering Approach for Hospitalized Patients with Dysmagnesemia
Sy‐Go, Janina Paula T. , Nissaisorakarn, Voravech , Dumancas, Carissa , Keddis, Mira T. , Kattah, Andrea G. , Pattharanitima, Pattharawin , Vallabhajosyula, Saraschandra , Mao, Michael A. , Erickson, Stephen B., Cheungpasitporn, Wisit , Sy-Go, Janina Paula T, Nissaisorakarn, Voravech , Dumancas, Carissa Y, Keddis, Mira , Pattharanitima, Pattharawin , Vallabhajosyula, Saraschandra , Mao, Michael A , Dillon, John J, Cheungpasitporn, Wisit , Thongprayoon, Charat , Qureshi, Fawad , Garovic, Vesna D. , Dillon, John

Mayo Clinic

Diagnostics | November 15, 2021 | Volume: 11 | Issue: 11 | Pages: 2119

10.3390/diagnostics11112119 | PMID 34829467 Get It

Background: The objectives of this study were to classify patients with serum magnesium derangement on hospital admission into clusters using unsupervised machine learning approach and to evaluate the mortality risks among these distinct clusters. Methods: Consensus cluster analysis was performed based on demographic information, principal diagnoses, comorbidities, and laboratory data in hypomagnesemia (serum magnesium ≤ 1.6 mg/dL) and hypermagnesemia cohorts (serum magnesium ≥ 2.4 mg/dL). Each cluster’s key features were determined using the standardized mean difference. The associations of the clusters with hospital mortality and one-year mortality were assessed. Results: In hypomagnesemia cohort (n = 13,320), consensus cluster analysis identified three clusters. Cluster 1 patients had the highest comorbidity burden and lowest serum magnesium. Cluster 2 patients had the youngest age, lowest comorbidity burden, and highest kidney function. Cluster 3 patients had the oldest age and lowest kidney function. Cluster 1 and cluster 3 were associated with higher hospital and one-year mortality compared to cluster 2. In hypermagnesemia cohort (n = 4671), the analysis identified two clusters. Compared to cluster 1, the key features of cluster 2 included older age, higher comorbidity burden, more hospital admissions primarily due to kidney disease, more acute kidney injury, and lower kidney function. Compared to cluster 1, cluster 2 was associated with higher hospital mortality and one-year mortality. Conclusion: Our cluster analysis identified clinically distinct phenotypes with differing mortality risks in hospitalized patients with dysmagnesemia. Future studies are required to assess the application of this ML consensus clustering approach to care for hospitalized patients with dysmagnesemia.
Consensus core clinical data elements for meningiomas (v2021.1)
Nassiri, Farshad , Wang, Justin Z. , Jenkinson, Michael D. , Drummond, Kate, Zhou, Yueren , Snyder, James M. , Santarius, Thomas , Suppiah, Suganth , Poisson, Laila , Gaillard, Francesco, Rosenthal, Mark , Tsang, Derek S. , Aldape, Kenneth , Zadeh, Gelareh , Kaufmann, Timothy, Snyder, James , Au, Karolyn , Barnholtz‐Sloan, Jill S. , Brastianos, Priscilla K. , Gaillard, Francesco, Kaufmann, Timothy J.

Mayo Clinic

Neuro-Oncology | November 15, 2021 | Volume: 24 | Issue: 5 | Pages: 683-693

10.1093/neuonc/noab259 | PMID 34791428 Get It

AbstractBackgroundWith increasing molecular analyses of meningiomas, there is a need to harmonize language used to capture clinical data across centers to ensure that molecular alterations are appropriately linked to clinical variables of interest. Here the International Consortium on Meningiomas presents a set of core and supplemental meningioma-specific common data elements (CDEs) to facilitate comparative and pooled analyses.MethodsThe generation of CDEs followed the 4-phase process similar to other National Institute of Neurological Disorders and Stroke (NINDS) CDE projects: discovery, internal validation, external validation, and distribution.ResultsThe CDEs were organized into patient- and tumor-level modules. In total, 17 core CDEs (10 patient level and 7 tumor level) as well as 14 supplemental CDEs (7 patient level and 7 tumor level) were defined and described. These CDEs are now made publicly available for dissemination and adoption.ConclusionsCDEs provide a framework for discussion in the neuro-oncology community that will facilitate data-sharing for collaborative research projects and aid in developing a common language for comparative and pooled analyses. The meningioma-specific CDEs presented here are intended to be dynamic parameters that evolve with time and The Consortium welcomes international feedback for further refinement and implementation of these CDEs.
Pediatric Celiac Disease: A Review of Diagnostic Testing and Guideline Recommendations
Horton, Rachel K. , Hagen, Catherine E. , Snyder, Melissa R. , Hagen, Catherine E

Mayo Clinic

The Journal of Applied Laboratory Medicine | November 15, 2021 | Volume: 7 | Issue: 1 | Pages: 294-304

10.1093/jalm/jfab143 | PMID 34996069 Get It

Abstract Background The history of how our knowledge of celiac disease (CD) evolved points to its importance in children. Although it is now appreciated that CD can present at any age, it was originally thought to occur only in children and, if untreated, led to serious consequences. Content This review includes a brief discussion of small bowel physiology and the pathogenesis of CD. Next, the varied clinical presentations of CD in children are reviewed, including both gastrointestinal and nongastrointestinal manifestations and how these contribute to the difficulty in diagnosis. In addition, information on specific conditions that are associated with CD is presented, particularly as it applies to diagnostic testing of apparently asymptomatic children. The review will also focus on diagnostic testing available for CD and their general performance characteristics. The review will end with a comparison between published guidelines from the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition for diagnosis of pediatric CD. In particular, this review will focus on differences in the incorporation of serologic and genetic testing, and the role of biopsies in the pediatric population. Summary It is important for laboratorians to understand the evolution of diagnostic guidelines for pediatric CD and how serologic and genetic testing are being applied to and interpreted in this particular patient group.
Correlation of ANA Characteristics with pANCA IFA Interference
Larkey, Nicholas E., Denome, Ashley M, Snyder, Melissa R, Snyder, Melissa R

Mayo Clinic

The Journal of Applied Laboratory Medicine | November 15, 2021 | Volume: 7 | Issue: 1 | Pages: 75-80

10.1093/jalm/jfab122 | PMID 34996078 Get It

Abstract Background Antineutrophil cytoplasmic antibody (ANCA) testing by the indirect immunofluorescence assay (IFA) is important for the diagnosis of autoimmune vasculitis. A common analytical interference for ANCA-IFA is the presence of an antinuclear antibody (ANA), which can cause an apparent perinuclear ANCA (pANCA) result on ethanol-fixed neutrophils. Here, the association of ANA patterns, titers, and concentrations with pANCA interference is investigated. Methods Samples positive for ANA by IFA with homogeneous, speckled, dense fine speckled (DFS), and centromere patterns were tested for ANA by enzyme immunoassay (EIA)] and for ANCA by IFA on ethanol-fixed neutrophils. Titers and concentrations were determined for the ANA-IFA and EIA, respectively, and correlated with the frequency of pANCA interpretations. Results For ANA-EIA positive samples (≥1.1U), 20.0% led to a pANCA interpretation compared to 5.1% for negative samples (≤1.0U). For samples positive by ANA-IFA, 12.9% resulted in a pANCA interpretation. Interference on pANCA correlated with ANA-IFA titer, with ANA titers ≥1:1280 identified as pANCA positive in 20.9% of samples compared to 9.7% for titers <1:1280. There was also a correlation with ANA pattern, as homogeneous samples were most likely to be called positive for pANCA (31.7%), followed by speckled (8.8%), DFS (6.8%), and centromere (3.6%). Conclusions Positivity for ANA by EIA is associated with increased prevalence of pANCA interpretation. Samples positive for ANA by IFA also demonstrated this association, particularly with higher-titer, homogeneous patterns. Laboratories can use this information to determine an optimal workflow for when investigating potential pANCA interferences.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Chang, Julie , Christian, Beth , Advani, Ranjana H. , Bartlett, Nancy L. , Vos, Sven de , Dholaria, Bhagirathbhai , Fakhri, Bita , Fayad, Luis , Glenn, Martha, Hernandez‐Ilizaliturri, Francisco J. , Kaminski, Mark , Krivacic, Susan, LaCasce, Ann S. , Narkhede, Mayur , Rabinovitch, Rachel , Roberts, Kenneth B. , Smith, Stephen D. , Svoboda, Jakub , Swinnen, Lode J., Tuscano, Joseph M. , Dwyer, Mary A., Sundar, Hema, Dholaria, Bhagirathbhai R , Bartlett, Nancy L , Advani, Ranjana H , Fakhri, Bita , Zelenetz, Andrew D. , Gordon, Leo I. , Abramson, Jeremy S. , Budde, Lihua E. , Caimi, Paolo F. , Habermann, Thomas M. , Hsi, Eric D. , Hu, Boyu , Kelsey, Chris R. , Khan, Nadia , Lim, Megan S. , Ramakrishnan, Praveen , Reid, Erin G , Saeed, Hayder , Vose, Julie M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 15, 2021 | Volume: 19 | Issue: 11 | Pages: 1218-1230

10.6004/jnccn.2021.0054 | PMID 34781267 Get It

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Probands on Concomitant Risk to First-Degree Relatives
Antwi, Samuel O. , Rabe, Kari G. , Bamlet, William R. , Meyer, Margaret, Chandra, Shruti, Fagan, Sarah , Hu, Chunling, Couch, Fergus J., McWilliams, Robert R. , Oberg, Ann L. , Petersen, Gloria M., Chen, Chen , Fagan, Sarah E , Chaffee, Kari G. , Chen, C , Antwi, Samuel O , Bamlet, William R , McWilliams, Robert R , Meyer, Margaret, Chandra, Shruti, Hu, Chunling, Couch, Fergus J., Oberg, Ann L , Petersen, Gloria M.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 15, 2021 | Volume: 31 | Issue: 2 | Pages: 372-381

10.1158/1055-9965.epi-21-0745 | PMID 34782396 Get It

Abstract Background: ABO blood group is associated with pancreatic cancer risk. Whether ABO blood group alone or when combined with inherited mutation status of index pancreatic cancer cases (probands) can enhance pancreatic cancer risk estimation in first-degree relatives (FDR) is unclear. We examined FDRs' risk for pancreatic cancer based on probands' ABO blood group and probands' cancer susceptibility gene mutation status. Methods: Data on 23,739 FDRs, identified through 3,268 pancreatic cancer probands, were analyzed. Probands' ABO blood groups were determined serologically or genetically, and 20 cancer susceptibility genes were used to classify probands as “mutation-positive” or “mutation-negative.” SIRs and 95% confidence intervals (CI) were calculated, comparing observed pancreatic cancer cases in the FDRs with the number expected in SEER-21 (reference population). Results: Overall, FDRs had 2-fold risk of pancreatic cancer (SIR = 2.00; 95% CI = 1.79–2.22). Pancreatic cancer risk was higher in FDRs of mutation-positive (SIR = 3.80; 95% CI = 2.81–5.02) than mutation-negative (SIR = 1.79; 95% CI = 1.57–2.04) probands (P < 0.001). The magnitude of risk did not differ by ABO blood group alone (SIRblood-group-O = 1.57; 95% CI = 1.20–2.03, SIRnon-O = 1.83; 95% CI = 1.53–2.17; P = 0.33). Among FDRs of probands with non-O blood group, pancreatic cancer risk was higher in FDRs of mutation-positive (SIR = 3.98; 95% CI = 2.62–5.80) than mutation-negative (SIR = 1.66; 95% CI = 1.35–2.03) probands (P < 0.001), but risk magnitudes were statistically similar when probands had blood group O (SIRmutation-positive = 2.65; 95% CI = 1.09–5.47, SIRmutation-negative = 1.48; 95% CI = 1.06–5.47; P = 0.16). Conclusions: There is a range of pancreatic cancer risk to FDRs according to probands' germline mutation status and ABO blood group, ranging from 1.48 for FDRs of probands with blood group O and mutation-negative to 3.98 for FDRs of probands with non-O blood group and mutation-positive. Impact: Combined ABO blood group and germline mutation status of probands can inform pancreatic cancer risk estimation in FDRs.
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary
Pringsheim, Tamara, Day, Gregory S. , Smith, Don B., Rae-Grant, Alex, Licking, Nicole, Armstrong, Melissa J., Bie, Rob M.A. de , Roze, Emmanuel, Miyasaki, Janis M., Hauser, Robert A. , Espay, Alberto J., Martello, Justin P., Gurwell, Julie A., Billinghurst, Lori, Sullivan, Kelly, Fitts, Michael S., Cothros, Nicholas, Hall, Deborah A., Rafferty, Miriam, Hagerbrant, Lynn, Hastings, Tara, O'Brien, Mary Dolan, Silsbee, Heather, Gronseth, Gary, Pringsheim, Tamara, Day, Gregory S., Smith, DonB., Rae-Grant, Alex, Licking, Nicole, Armstrong, Melissa J., Bie, Rob M. A. de, Roze, Emmanuel, Miyasaki, Janis M., A.Hauser, Robert, Espay, Alberto J., Martello, Justin P., Gurwell, Julie, Billinghurst, Lori, Sullivan, Kelly, Fitts, Michael S., Cothros, Nicholas, Hall, Deborah A., Rafferty, Miriam, Hagerbrant, Lynn, Hastings, Tara, O’Brien, Mary Dolan, Silsbee, Heather, Gronseth, Gary, Lang, Anthony E., Miyasaki, Janis M. , Armstrong, Melissa J. , Roze, Emmanuel , Silsbee, Heather M. , de Bie, Rob M A , Lang, Anthony E , Day, Gregory S , Hauser, Robert A , Silsbee, Heather M , Armstrong, Melissa J , Pringsheim, Tamara, Smith, Don B., Rae-Grant, Alex, Licking, Nicole, Armstrong, Melissa J., Roze, Emmanuel, Espay, Alberto J., Martello, Justin P., Gurwell, Julie A., Billinghurst, Lori, Sullivan, Kelly, Fitts, Michael S., Cothros, Nicholas, Hall, Deborah A., Rafferty, Miriam, Hagerbrant, Lynn, Hastings, Tara, O'Brien, Mary Dolan, Gronseth, Gary, Pringsheim, Tamara, Day, Gregory S., Smith, DonB., Rae-Grant, Alex, Licking, Nicole, Armstrong, Melissa J., Bie, Rob M. A. de, Miyasaki, Janis M., A.Hauser, Robert, Espay, Alberto J., Martello, Justin P., Gurwell, Julie, Billinghurst, Lori, Sullivan, Kelly, Fitts, Michael S., Cothros, Nicholas, Hall, Deborah A., Rafferty, Miriam, Hagerbrant, Lynn, Hastings, Tara, O’Brien, Mary Dolan, Silsbee, Heather, Gronseth, Gary, Lang, Anthony E.

Mayo Clinic

Neurology | November 15, 2021 | Volume: 97 | Issue: 20 | Pages: 942-957

10.1212/wnl.0000000000012868 | PMID 34782410 Get It

Abstract 17189: Radiation-induced Accelerated Multi-valve Disease In A Patient With Subaortic Membrane
Garcia‐Arango, Mariana , Vinnakota, Shravya , Villarraga, Hector R.

Mayo Clinic

Circulation | November 15, 2021 | Volume: 144 | Issue: Suppl_2 | Pages: No page available

10.1161/circ.144.suppl_2.17189 Get It

A 69-year-old woman with history of right breast cancer status post lumpectomy and radiation (4.2 cGy) 18 months prior, presented with progressive NYHA class III dyspnea. TTE obtained prior to her cancer diagnosis was notable for normal LV size and wall thickness, a subaortic membrane with systolic mean Doppler gradient of 21 mmHg and a mildly thickened mitral valve without significant stenosis or regurgitation. On presentation, TTE was notable for severely increased concentric LV wall thickness (LV mass index 140 g/m 2 ), preserved ejection fraction, increased RV wall thickness, subaortic stenosis with systolic mean Doppler gradient 35 mmHg, moderate-severe aortic regurgitation, thickened mitral valve with posterior leaflet tethering and anterior leaflet override causing severe mitral regurgitation and moderate mitral stenosis (valve area 1.7 cm 2 by pressure half-time). She underwent a surgical intervention with septal myectomy, subaortic membrane resection, aortic root reconstruction, aortic and mitral valve replacement with bioprostheses. She did well post-operatively and had complete resolution of symptoms following cardiac rehabilitation. Radiation-induced valvular heart disease is linked to the total dose of radiation, use of sequential chemotherapy and time since irradiation, with a typical latency of 10-20 years. However, there is paucity of data regarding the influence of these variables in patients with pre-existing valve disease. This case illustrates dramatic acceleration of underlying aortic and mitral valve pathology in a patient with a subaortic membrane, 18 months after radiation. We also noted development of significant concentric LV hypertrophy that was disproportionate to the degree of obstruction across the sub-aortic membrane. Potential candidates for radiation therapy must be carefully screened for pre-existing valve disease, which should warrant increased vigilance and early screening for progressive valve disease.